The estimated Net Worth of Annette North is at least $4.04 Million dollars as of 9 February 2022. Ms. North owns over 669 units of Turning Point Therapeutics Inc stock worth over $889,013 and over the last 6 years she sold TPTX stock worth over $24,285. In addition, she makes $3,126,300 as Executive Vice President, General Counsel, and Secretary at Turning Point Therapeutics Inc.
Annette has made over 6 trades of the Turning Point Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 669 units of TPTX stock worth $24,285 on 9 February 2022.
The largest trade she's ever made was exercising 25,000 units of Turning Point Therapeutics Inc stock on 1 February 2021 worth over $425,000. On average, Annette trades about 8,506 units every 41 days since 2019. As of 9 February 2022 she still owns at least 11,696 units of Turning Point Therapeutics Inc stock.
You can see the complete history of Ms. North stock trades at the bottom of the page.
Annette Christine North serves as Executive Vice President, General Counsel, Secretary of the Company. Previously, Ms. North served as Senior Vice President, General Counsel of Kura Oncology, Inc., a publicly held clinical-stage biopharmaceutical company, from January 2015 to April 2019, and as General Counsel and Secretary of Wellspring Biosciences, Inc. and its parent company, Araxes Pharma LLC. Ms. North served as Senior Vice President and General Counsel of Ambit Biosciences Corporation, a publicly held biopharmaceutical company, from June 2013 to January 2015, and from January 2009 to December 2014, Ms. North was an independent legal consultant to a number of life sciences companies. From 2000 to 2008, Ms. North served as General Counsel and held a number of other positions at SGX Pharmaceuticals, Inc., a publicly held biopharmaceutical company which was acquired by Eli Lilly and Company in 2008. Earlier in her career, Ms. North served in legal positions at Axys Pharmaceuticals, Inc., and Sequana Therapeutics, Inc., and as a solicitor in law firms in London, England and Melbourne, Australia. Ms. North received both her Bachelor of Commerce and her Bachelor of Laws from the University of Melbourne, Australia.
As the Executive Vice President, General Counsel, and Secretary of Turning Point Therapeutics Inc, the total compensation of Annette North at Turning Point Therapeutics Inc is $3,126,300. There are 2 executives at Turning Point Therapeutics Inc getting paid more, with Yi Larson having the highest compensation of $12,579,400.
Annette North is 54, she's been the Executive Vice President, General Counsel, and Secretary of Turning Point Therapeutics Inc since 2019. There are 7 older and 12 younger executives at Turning Point Therapeutics Inc. The oldest executive at Turning Point Therapeutics Inc is Garry Nicholson, 65, who is the Independent Director.
Over the last 6 years, insiders at Turning Point Therapeutics Inc have traded over $45,947,838 worth of Turning Point Therapeutics Inc stock and bought 2,385,408 units worth $60,168,920 . The most active insiders traders include Plc Gsk, Patrick Machado, and Advisors Llc Orbi Med Capit.... On average, Turning Point Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,727,594. The most recent stock trade was executed by Paolo Tombesi on 27 July 2022, trading 1,183 units of TPTX stock currently worth $88,654.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Turning Point Therapeutics Inc executives and other stock owners filed with the SEC include: